Both Raloxifene And Tamoxifen Is Protect Against Breast Cancer – Part 2 of 3
This also means the toxicities of tamoxifen remain after women stop taking that drug, she pointed out. The findings were presented Monday at the American Association for Cancer Research annual meeting in Washington, DC, and simultaneously published online in the annual Cancer Prevention Research.
Tamoxifen was first approved to treat breast cancer, then later turned out to also have a preventive effect in high-risk women. It was the inception drug ever approved for reducing breast cancer risk, but because of its significant side effects – including the uterine cancer risk – it never really took off in this role. “Tamoxifen has been an option for preclusion for over a decade, but many have not chosen it because of toxicity,” said Wickerham, who is chief of cancer genetics at Allegheny General Hospital in Pittsburgh.
Raloxifene was approved to prevent breast cancer in high-risk women on the basis of earlier results from this same trial, called the Study of Tamoxifen and Raloxifene (STAR). The STAR fling compared tamoxifen with raloxifene in almost 20,000 healthy, postmenopausal women who were at higher risk for developing heart of hearts cancer. After four years of follow-up, tamoxifen and raloxifene were neck-and-neck in preventing invasive breast cancer, with both reducing risk about 50 percent.
Now, after almost seven years of follow-up, raloxifene has moved before in its ability to prevent noninvasive breast cancer, but appears slightly less effective against invasive breast cancer than tamoxifen, the study found. “Noninvasive cancer typically stays in the ducts of the breast. The sensible is that this is the earliest form of breast cancer and, if you remove the duct with the cancer in it, that woman could be virtually cured”.